MULTIDISCIPLINARY HEAD and NECK CANCERS SYMPOSIUM

EXTRAORDINARY CARE: Collaborative, Targeted, Diverse, Patient Centered

February 24-26, 2022
JW Marriott Phoenix Desert Ridge Resort and Spa
Phoenix, Arizona

POCKET PROGRAM

Social Q&A Access:
www.astro.org/HNSocialQA
# TABLE OF CONTENTS

**NETWORKING OPPORTUNITIES** 1-2
- Early-career and Trainee Networking Luncheons
- Poster Session and Networking Reception
- Industry Satellite Symposia
- Industry-Expert Theater

**GENERAL INFORMATION** 3-6
- Abstracts and Digital Poster Viewing
- Press and Media
- Health and Safety Measures
- Registration Location and Hours
- Exhibit Hall Location and Hours
- Speaker Ready Room Location & Hours
- Passport to Prizes (Enter to win!)
- Social Q&A Information and Instructions

**KEYNOTE SPEAKERS** 7

**CONTINUING MEDICAL EDUCATION** 7-11
- Continuing Education Credits Information
- Evaluation Instructions and Deadline
- Planning Committees

**PROGRAM AGENDA** 12-20

**EXHIBITOR LISTING** 21-27

**onDemand MEETING INFORMATION** 28

**UNRESTRICTED EDUCATIONAL GRANT SUPPORTER** 32
NETWORKING OPPORTUNITIES

EARLY-CAREER AND TRAINEE NETWORKING LUNCHEONS

Choosing Your Career Path
Thursday, February 24, 12:30 p.m. – 1:30 p.m.
Grand Canyon Ballroom 4-5

Launching Your Successful Career
Friday, February 25, 12:20 p.m. – 1:20 p.m.
Grand Canyon Ballroom 4-5

The Early-career and Trainee Networking Luncheons offer attendees an invaluable opportunity to speak with and learn from experts in the head and neck cancer care community. By attending, you will gain meaningful insight into career paths and development that will help support you in your medical career. (Note: Early-career is defined as any attendee who is less than three years out of their training.) Those interested in attending must register for these free, ticketed events.

POSTER SESSION AND NETWORKING RECEPTION
Thursday, February 24, 4:30 p.m. – 5:30 p.m.
Exhibit Hall, Grand Canyon Ballroom 6-8

INDUSTRY SATELLITE SYMPOSIA
Who’s In Your Waiting Room? Multidisciplinary Perspectives on Management of CSCC of the Head and Neck
Thursday, February 24, 2022, 6:00 p.m. - 7:30 p.m.
Registration: 5:30 p.m. – 6:00 p.m.
Grand Canyon Ballroom 11, 12 & 13: Dinner and Symposia
To register or learn more, visit www.medscape.org/townhall/h&n-cscc

Accreditation Statement
In support of improving patient care, Medscape LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation
Physicians: Medscape LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an independent medical educational grant from Regeneron Pharmaceuticals Inc., and Sanofi Genzyme.
Opportunities in Head and Neck Cancer: Promising Phase II Data Combining IAPs with Radiotherapy

Thursday, February 24, 2022, 5:30 p.m. - 6:30 p.m.
Grand Canyon Ballroom 9 & 10

Credit Designation
This Non-CME Informational/Educational Program refers to any educational activity that is independently organized, held in conjunction with the 2022 Multidisciplinary Head and Neck Cancers Symposium and does not carry Continuing Medical Education (CME) credit.

Supporter Statement
This event is supported independently by Merck KGaA Darmstadt Germany. To learn more about Merck KGaA Darmstadt Germany, visit www.merckgroup.com.

The 2022 Multidisciplinary Head and Neck Cancers Symposium Steering Committee have reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposia (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2022 Multidisciplinary Head and Neck Cancers Symposium program. ISS and non-CME ISS refers to any educational activity that is independently organized and held in conjunction with the 2022 Multidisciplinary Head and Neck Cancers Symposium. This includes any educational activity that carries Continuing Medical Education (CME) credit not sponsored by ASTRO.

INDUSTRY-EXPERT THEATER

Castle Biosciences Industry-Expert Theater
Friday, February 25, 2022, 5:30 p.m. – 6:30 p.m.
Grand Canyon Ballroom 9 & 10

DecisionDx-SCC: Use of a 40-gene expression profile to refine patient metastatic risk in head and neck cutaneous squamous cell carcinoma

An in-depth review of cutaneous squamous cell carcinoma (cSCC) as an emerging problem in the U.S. with unmet clinical need for improved risk assessment. DecisionDx-SCC is a 40-gene expression profile test that predicts metastatic risk for cSCC patients with one or more risk factors. Integrating DecisionDx-SCC and clinicopathologic features for cSCC and cSCC-HN patients can inform management decisions within established guidelines.

Speaker: Andres M. Bur, MD, FACS, is an Associate Professor of Otolaryngology – Head and Neck Surgery, Director of Robotic and Minimally Invasive Head and Neck Surgery at the University of Kansas.
**GENERAL INFORMATION**

**ABSTRACTS**
The full text of the abstracts selected for presentation is available on the meeting website and all abstracts are published in an issue of the *International Journal of Radiation Oncology · Biology · Physics* (www.redjournal.org). To view the abstracts online, visit www.headandnecksymposium.org.

All abstracts to be presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium are embargoed until 8:00 a.m. Mountain time, Thursday, February 24, 2022. If you have any questions about the embargo policy, please contact press@astro.org.

**DIGITAL POSTER VIEWING**
Posters are accessible online in the Virtual Poster Library in addition to digital poster viewing stations in the Exhibit Hall (Grand Canyon Ballroom 6-8). Posters are searchable by keyword, presenter name, institution or poster number. The Virtual Poster Library allows all attendees to view posters online while at the symposium (on personal devices or at the digital poster viewing stations in the Exhibit Hall) and online for a limited period of time after the symposium concludes. Attendees interested in more information can also contact authors through the Virtual Poster Library with questions regarding their poster.

**POSTER SESSIONS**
Poster Sessions will occur throughout the meeting, giving poster authors the opportunity to discuss their research with symposium attendees. Poster Sessions will take place at the poster viewing stations in the Exhibit Hall (Grand Canyon Ballroom 6-8) during the following times:

- **Poster Session I & Coffee Break**
  Thursday, February 24, 3:00 p.m. - 3:30 p.m.

- **Poster Session II & Networking Reception**
  Thursday, February 24, 4:30 p.m. - 5:30 p.m.

- **Poster Session III & Coffee Break**
  Friday, February 25, 10:25 a.m. - 10:50 a.m.

- **Poster Session IV & Coffee Break**
  Friday, February 25, 2:35 p.m. - 3:00 p.m.
PRESS AND MEDIA
ASTRO offers resources for journalists covering the 2022 Multidisciplinary Head and Neck Cancers Symposium, including an online press kit at www.astro.org/HNpress. Rooms for press/media interviews in Phoenix are available on request. Contact ASTRO’s media relations team at press@astro.org with any questions.

HEALTH AND SAFETY MEASURES
ASTRO will be requiring all attendees and exhibit booth personnel to attest that they have been fully vaccinated against COVID-19 prior to receiving their badge and entering sessions. Masks are mandatory to attend all sessions and in the Exhibit Hall. Please visit www.astro.org/headandnecksafety for more information on health and safety measures.

HOTEL INFORMATION
JW Marriott Phoenix Desert Ridge Resort and Spa
5350 E Marriott Drive
Phoenix, AZ 85054
Phone: 480-293-5000

REGISTRATION LOCATION AND HOURS
Attendees will be able to pick up their badges at the Registration and Information Desk, located in the Grand Saguaro Foyer, during the following hours:

Wednesday, February 23  4:00 p.m. – 6:00 p.m.
Thursday, February 24  7:00 a.m. – 4:30 p.m.
Friday, February 25  7:00 a.m. – 5:30 p.m.
Saturday, February 26  7:00 a.m. – 12:15 p.m.

EXHIBIT HALL LOCATION AND HOURS
The Exhibit Hall is located in Grand Canyon Ballroom 6-8 and will be open during the following hours:

Thursday, February 24  7:00 a.m. – 5:30 p.m.
Friday, February 25  7:00 a.m. – 3:00 p.m.

SPEAKER READY ROOM
All presenters are required to check in at the Speaker Ready Room at least two hours before their session takes place to upload their presentation. Computers are available to preview your slides. Located in Wildflower A, the Speaker Ready Room will be open during the following hours:

Wednesday, February 23  4:00 p.m. – 6:00 p.m.
Thursday, February 24  6:45 a.m. – 4:30 p.m.
Friday, February 25  6:45 a.m. – 5:30 p.m.
Saturday, February 26  6:45 a.m. – 12:15 p.m.
SESSION ROOMS
All sessions will take place in the Grand Saguaro Ballroom.

TRAVEL GRANT WINNERS
Congratulations to the 2022 Multidisciplinary Head and Neck Cancers Symposium travel grant winners, awarded based on the high quality of their submitted abstracts.

Robert Saddawi-Konefka, MD, PhD
University of California, San Diego
“Neoadjuvant ImmunoradiotHerapy in a Tobacco-Signature Preclinical Oral Squamous Cell Carcinoma Model”

Molly Heft-Neal, MD
University of Michigan
“Loss of HPV 16-E2 Predicts Disease Free Survival and Promoted Platinum Resistance in Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma”

PASSPORT TO PRIZES
Enter a drawing to win prizes by participating in the Passport to Prizes program. During badge pick-up, all attendees will receive a passport document. To participate, attendees need to visit participating booths in the Exhibit Hall to receive a stamp in their passport. All stamps must be completed on the passport for eligibility. The drawing will take place Friday, February 25 at 3:00 p.m. in the Grand Saguaro Ballroom (at the start of the session titled Hot Topic: Options in Advanced Skin Squamous Cell Carcinoma). Two winners will receive a $100 AMEX gift card. Good luck! (If an exhibitor is unavailable for a stamp during the specified break and mealtimes, please notify the Registration and Information Desk.)

AGE REQUIREMENTS FOR ATTENDEES
Due to the detailed nature of the programs and forums, no one under the age of 18 will be admitted to any official symposium function. This includes, but is not limited to, all symposium sessions and the exhibits/food room.

BADGES
Attendees and guests are requested to always wear their name badge during the meeting. This is your ticket into the session rooms and verifies your registration.

DRESS
Business Casual

LOST AND FOUND
Lost and found items are available at the Registration and Information Desk (Grand Saguaro Foyer). Please stop by to
inquire about any missing items. Items found can be brought to the Registration and Information Desk. Any unclaimed items will be turned into hotel security at the end of each day.

**MEALS**

**Breakfast**

Continental breakfast will be provided on Thursday and Friday in the Exhibit Hall (Grand Canyon Ballroom 6-8) and on Saturday in the Grand Saguaro Foyer.

**Coffee Breaks**

Morning coffee breaks will be provided on Thursday and Friday in the Exhibit Hall (Grand Canyon Ballroom 6-8) and on Saturday in the Grand Saguaro Foyer.

Afternoon coffee breaks will be provided on Thursday and Friday in the Exhibit Hall (Grand Canyon Ballroom 6-8).

Poster Sessions will be featured during the Thursday afternoon coffee break, and during both Friday coffee breaks. Attend these sessions to hear poster authors present their research and ask questions.

**Lunch**

Lunch will be provided on Thursday and Friday in the Exhibit Hall (Grand Canyon Ballroom 6-8).

**RECORDING**

No audio recording, video recording or flash photography is permitted at any time during the meeting.

**SOCIAL Q&A**

Attendees can use their own electronic devices, (e.g., phone, iPad, laptop) or floor microphones to submit questions to the speakers and moderators. Attendees will be able to view the questions that others have asked and can upvote questions they want answered. Some speakers may also utilize the technology to poll the audience with interactive, audience response questions.

To access the Social Q&A platform, as well as any speaker polls, go to [www.astro.org/HNSocialQA](http://www.astro.org/HNSocialQA). Navigate to the current session and, if necessary, select the appropriate speaker from the given list when asking a question.
KEYNOTE SPEAKERS

Sharon Spencer, MD
University of Alabama at Birmingham

Charles Moore, MD
Emory University

Nancy Lee, MD, FASTRO
Memorial Sloan Kettering Cancer Center

CONTINUING MEDICAL EDUCATION

PROGRAM CONTENT/FORMAT
The 2022 Multidisciplinary Head and Neck Cancers Symposium is a two-and-a-half-day meeting featuring interactive and case-based educational sessions that cover new multidisciplinary therapies, imaging, immunotherapy, treatment guidelines, supportive care and understanding disparities in head and neck cancer. A major focus is placed on the multidisciplinary nature of disease management and the incorporation of all treatment modalities to achieve best outcomes. Oral abstract and poster sessions will highlight cutting-edge science and evidence-based practice. Attendees will be able to examine multidisciplinary approaches for treating head and neck cancer, as well as novel therapies that show promise in improving outcomes.

STATEMENT OF NEED
The management of head and neck cancer (HNC) is rapidly evolving with newer modality treatments available to patients. These modalities include minimally invasive surgery, newer radiation targeting techniques, novel targeted therapy and immunotherapy. In addition, the re-classification of patients with locoregionally advanced human papilloma (HPV)+ oropharyngeal carcinoma into earlier stage groups have engendered some confusion surrounding treatment planning. Many large clinical trials are maturing to establish new treatments or standards of care in HNC patients. Improving QOL in our patients who are living longer is a critical need. There is a need to review current guidelines for HNC survivorship care and identify areas of unmet need. It is imperative that the medical professionals involved in the care of HNC patients remain current in the expanding knowledge of this cancer. This meeting provides attendees the opportunity to gain exposure to the latest science in HNC. Attendees need to determine when and how the latest science will affect their day-to-day practice, and thus be able to narrow
competency gaps across the management of different HNC subtypes and stages. They also need to understand how to reduce disparities in the care of cancer patients.

**PROGRAM OBJECTIVES**

Upon completion of this live activity, attendees should be able to do the following:

- Explain the importance of multidisciplinary care in head and neck cancer (HNC) and how to best apply it for optimal outcomes.
- Describe key advances in systemic therapy, including targeted therapy and immunotherapy in HNC.
- Discuss recent advances in minimally invasive surgery in HNC and when to apply it in treating early and locally advanced disease.
- Illustrate how we can improve disparities in head and neck cancer care.
- Determine the importance of interventions in survivorship clinics for long-term side effects.
- Describe key advances in radiation therapy delivery, targeting and differences between various modalities, including novel treatment approaches such as proton and FLASH radiotherapy.
- Discuss complex cases in HNC and how to best utilize current knowledge for decision making.
- Manage toxicities related to the management of head and neck cancer.
- Summarize key recent advances in HNC biology.
- Summarize key recent advances in HNC imaging.
- Discuss and implement standard treatment guidelines for various subtypes of HNCs.

**ELEMENTS OF COMPETENCE**

This educational forum has been designed to narrow the competency gaps of:

- Patient Care
- Medical Knowledge
- Practice-based Learning and Improvement
- Interpersonal Skills and Communication
- Professionalism
- Systems-based Practice
- Patient-centered Care
- Work in Interdisciplinary Teams
- Evidence-based Practice
- Quality Improvement
- Professional Standing
- Commitment to Lifelong Learning
- Cognitive Expertise
- Roles/Responsibilities
- Interprofessional Communication
- Teams and Teamwork
These are 16 of the 19 core competencies embraced by the American Board of Medical Specialties, the Accreditation Council for Graduate Medical Education, the Institute of Medicine, the American Board of Radiology and the Accreditation Council for Continuing Medical Education.

TARGET AUDIENCE
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrist, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.

CONTINUING EDUCATION CREDITS

Physicians
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ASTRO designates this live activity for a maximum of 17.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicists
An application to the Commission on Accreditation of Medical Physics Education Program (CAMPEP) has been submitted for Medical Physics Continuing Education Credits (MPCEC).

EVALUATION
To be eligible to receive continuing education credit, attendees must complete the online evaluation by Tuesday, March 29, 2022. Please only evaluate the sessions you attended. To access your evaluation, log in to ASTRO Academy (academy.astro.org) with your ASTRO credentials.
- Stay on the home page and scroll down to “Pending Activities”. It will be under the sliding banner and on the right side of the page. If you don’t remember your password, click “Forgot My Password”.
- Click “2022 Multidisciplinary Head and Neck Cancers Symposium” to take the evaluation and to receive continuing education credits.

CERTIFICATES OF CREDIT
Participants can access, print and save their certificate all in the ASTRO Academy. Participants will have online access to their certificate upon completion of the evaluation.
Participants must complete the evaluation within 30 days. If you miss the deadline and still want to claim credits and receive a certificate, you will need to contact the Education Department (education@astro.org) and self-attest for your credits.

Physicist attendees will not receive certificates of credit from ASTRO. The names of physicist attendees will be sent to CAMPEP 45 days after the meeting. Any credits claimed after the evaluation deadline of **Tuesday, March 29, 2022**, will not be submitted by ASTRO to CAMPEP.

**DISCLOSURE OF VESTED INTEREST**
ASTRO is an accredited provider of continuing medical education. Since our accreditation is important to us, we plan activities that are compliant with the ACCME, and the content or format of CME activities and related materials will promote improvements or quality in health care and not a specific proprietary business interest or commercial bias. Planning Committee members and speakers are required to disclose the existence of any financial or other relationship with the manufacturer(s) of any commercial product(s) or provider(s) of any commercial service(s) discussed in an educational presentation.

Any conflicts of interest are resolved prior to participation. In addition to written disclosure, presenters will disclose any vested interest or their intention to discuss off-label use of pharmaceuticals or devices, if applicable, to the audience at the beginning of their presentation and in accordance with ACCME standards and Food and Drug Administration requirements.

In an effort to increase transparency and easy access to all disclosures, faculty, committee and presenter disclosure information will be available online for the 2022 Multidisciplinary Head and Neck Cancers Symposium. In addition to being available online at www.headandnecksymposium.org, disclosure slides will be shown at the beginning of each session. Disclosure information will not be printed in paper versions of the meeting materials.

**DISCLAIMER**
ASTRO is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASTRO of the uses, products or techniques presented.
The information contained in this program is current as of Wednesday, January 19, and is subject to change. Program changes, if any, will be posted online and an addendum may be printed for distribution on site.

**STEERING COMMITTEE**

**AHNS**
- Maie St. John, MD, PhD, UCLA Medical Center
- Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center (Symposium Chair)

**ASCO**
- Faye M. Johnson, MD, PhD, MD Anderson Cancer Center (Symposium Chair-elect)
- Alexander Pearson, MD, PhD, University of Chicago

**ASTRO**
- Quynh-Thu Le, MD, FASTRO, Stanford University (Immediate Past Chair)
- Zain Husain, MD, Sunnybrook Health Sciences Centre

**SITC**
- Julie E. Bauman, MD, MPH, University of Arizona Cancer Center
- Tullia C. Bruno, PhD, University of Pittsburgh

**PROGRAM COMMITTEE**

**AHNS**
- Kelly Malloy, MD, University of Michigan
- Mike Moore, MD, Indiana University School of Medicine

**ASCO**
- Ari Joseph Rosenberg, MD, University of Chicago
- Assuntina Gesualda Sacco, MD, UC San Diego Moores Cancer Center

**ASTRO**
- Farzan Siddiqui, MD, PhD, Henry Ford Cancer Center
- Minh Tam Truong, MBBS, Boston University School of Medicine

**SITC**
- Jessica L. Geiger, MD, Cleveland Clinic Cancer Center
- Dan P. Zandberg, MD, PhD, University of Pittsburgh Medical Center

**CONTENT ADVISORS**
- Margaret Brandwein, MD, Mount Sinai
- Joel Epstein, DMD, PhD, Cedars-Sinai Medical Center
- Heather Starmer, MA, CCC-SLP, BCS-S, Stanford University
Session planning information and references (as provided by faculty) are available on the meeting website at www.headandnecksymposium.org along with other resources to help extend and enhance learning.

All sessions will take place in the Grand Saguaro Ballroom.


WEDNESDAY, FEBRUARY 23

4:00 p.m. – 6:00 p.m.
Registration
Registration and Information Desk, Grand Saguaro Foyer

THURSDAY, FEBRUARY 24

7:00 a.m. – 4:15 p.m.
Registration
Registration and Information Desk, Grand Saguaro Foyer

7:00 a.m. – 8:00 a.m.
Continental Breakfast
Exhibit Hall, Grand Canyon Ballroom 6-8

7:50 a.m. – 8:00 a.m.
Welcome
Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS]

8:00 a.m. – 8:20 a.m.
Patient Perspective
Michael West

8:20 a.m. – 9:50 a.m.
Patient-centric Head and Neck Care
Moderator: Cherie-Ann Nathan, MD, Louisiana State University-Health, Shreveport, Louisiana [HNS]

• Comprehensive Rehabilitation of the Head and Neck Patient
  Heather Starmer, MA CCC-SLP, BCS-S, Stanford University, Stanford, California [SLP]

• Oral/Dental Needs in HNC Survivors
  Joel Epstein, DMD, MSD, Cedars-Sinai Medical Center, Los Angeles [OMFS]
• **Addressing the Psychological Aspects of Head and Neck Cancer**
  Elizabeth Cash, PhD, University of Louisville, Louisville, Kentucky [Psychologist]

• **The Artistry of Facial Prosthetics**
  Devin Okay, DDS, Mount Sinai Hospital, New York [Prosthodontist]

• **Nutrition in Head and Neck Cancer**
  Gloria Rubio, MBA, MS, University of California, San Diego [Nutritionist]

• **Q&A**

**9:50 a.m. – 10:35 a.m.**
Keynote I: Disparities in Head and Neck Cancer  
**Moderator:** Dan Zandberg, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh [M]  
  • Sharon Spencer, MD, University of Alabama at Birmingham, Birmingham, Alabama [R]  
  • Charles Moore, MD, Emory University, Atlanta [HNS]

**10:35 a.m. – 11:00 a.m.**  
Coffee Break  
📍 Exhibit Hall, Grand Canyon Ballroom 6-8

**11:00 a.m. – 12:30 p.m.**  
Escalation Strategies and Novel Approaches in Locally Advanced Head and Neck Cancer  
**Moderator:** Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona [M]  
  • **Immunotherapy in the Curative Intent Setting**
    Sana Karam, MD, PhD, University of Colorado, Denver [R]  
  • **The Role of Preop IO in Locally Advanced HNC**
    Ravi Uppaluri, MD, PhD, Brigham and Women’s Hospital, Boston [HNS]  
  • **Novel Radiosensitizers**
    Heath Skinner, MD, PhD, University of Pittsburgh, Pittsburgh [R]  
  • **Nasopharynx: Induction vs Adjuvant – where do we go from here?**
    Dimitrios Colevas, MD, Stanford University, Stanford, California [M]  
  • **Q&A**

**12:30 p.m. – 1:30 p.m.**  
Lunch  
📍 Exhibit Hall, Grand Canyon Ballroom 6-8
Early-career and Trainee Networking Luncheon: Choosing Your Career Path
(see page 1 for more information)

Grand Canyon Ballroom 4-5

Moderator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles, California [HNS]

Speakers:

- Julie Bauman, MD, MPH, University of Arizona, Tucson, Arizona [M]
- Katherine Hutcheson, PhD, MD, MD Anderson Cancer Center, Houston [SLP]
- Faye Johnson, MD, PhD, MD Anderson Cancer Center, Houston [Physician Scientist]
- Loren Mell, MD, University of California, San Diego [R]
- Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]

1:30 p.m. – 3:00 p.m.
K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session

Moderator: Maie St. John, MD, PhD, UCLA David Geffen, Los Angeles [HNS]

- Early Toxicity and Patient Reported Outcomes from a Phase II Trial of FDG-PET Response-based De-escalated Definitive Radiotherapy for p16+ Oropharynx Cancer
  Steven Allen, University of Michigan, Ann Arbor, Michigan
- Non-inferiority Margin and Nodal Analysis of De-escalated Adjuvant Radiation Therapy (DART) for HPV-related Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Preplanned Pooled Analysis of MC1273 & MC1675
  Daniel Ma, Mayo Clinic, Rochester, Minnesota
- Detection of Occult Recurrence Using Circulating HPV Tumor DNA among Patients Treated for HPV-driven Oropharyngeal Squamous Cell Carcinoma
  Glenn Hanna, Dana-Farber Cancer Institute, Harvard Medical School, Boston
- Kinetics of Circulating Human Papillomavirus (cHPV) DNA in Plasma and Oral Gargles from Patients with HPV-positive Oropharyngeal Cancer (OPC) Treated with Definitive Radiation Therapy
  Michelle Echevarria, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
- Immune-cell Signature Predicts Survival in Human Papillomavirus-associated Head and Neck Cancer
  Peter Zeng, Western University, London, Ontario, Canada
• Predicted Th2 Infiltrate is Associated with Outcome in HPV(-) Head and Neck Cancer
Mohamed Abdelhakiem, UPMC Hillman Cancer Center, Pittsburgh

• Loss of HPV 16-E2 Predicts Disease Free Survival and Promotes Platinum Resistance in Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
Molly Heft-Neal, University of Michigan, Ann Arbor, Michigan

• Neoadjuvant Immunoradiotherapy in a Tobacco-Signature Preclinical Oral Squamous Cell Carcinoma Model
Robert Saddawi-Konefka, University of California, San Diego

• HPV E5 Mediates Resistance to PD-1 Checkpoint Blockade via Inhibition of MHC and IFN Pathway
Andrew Sharabi, University of California, San Diego

3:00 p.m. – 3:30 p.m.
Poster Session I & Coffee Break
Exhibit Hall, Grand Canyon Ballroom 6-8

3:30 p.m. – 4:30 p.m.
Case Study & Debate: Curative Intent in Elderly and Frail
Moderator: Zain Husain, MD, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada [R]
Panelists:
• Paul Loren Swiecicki, MD, University of Michigan, Ann Arbor, Michigan [R]
• Susan McCammon, MD University of Alabama, Birmingham, Birmingham, Alabama [HNS]
• Loren Mell, MD, University of California, San Diego [R]
• Q&A

4:30 p.m. – 5:30 p.m.
Poster Session II & Networking Reception
Exhibit Hall, Grand Canyon Ballroom 6-8

FRIDAY, FEBRUARY 25

7:00 a.m. – 5:30 p.m.
Registration
Registration and Information Desk, Grand Saguaro Foyer

7:00 a.m. – 8:00 a.m.
Continental Breakfast
Exhibit Hall, Grand Canyon Ballroom 6-8
7:55 a.m. – 8:00 a.m.
Welcome
Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R]

8:00 a.m. 8:20 a.m.
Patient Perspective
Andy Pluemer

8:20 a.m. – 9:40 a.m.
HOT TOPIC: Early Oral Cavity
Moderator: Mike Moore, MD, Indiana University of Medicine, Indianapolis [HNS]
- Tumor Board
  Mark Varvares, MD, FACS, Massachusetts General Hospital, Boston [HNS]
- Pathologist’s Perspective
  Margaret Brandwein-Weber, MD, Mount Sinai, New York [Pathologist]
- Sentinel Node and Neck Dissection
  Stephen Lai, MD, PhD, FACS, MD Anderson Cancer Center, Houston [HNS]
- New Frontiers in Sx: Fluorescence Guided Sx
  Eben Rosenthal, MD, Vanderbilt University Medical Center, Nashville, Tennessee [HNS]
- Surgical Reconstruction
  Kelly Malloy, MD, University of Michigan, Ann Arbor, Michigan [HNS]

9:40 a.m. – 10:25 a.m.
Keynote II: Towards Personalization of HPV Related Oropharyngeal Carcinoma
Moderator: Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R]
- Nancy Lee, MD, FASTRO, Memorial Sloan Kettering Cancer Center, New York [R]

10:25 a.m. – 10:50 a.m.
Poster Session III & Coffee Break
Exhibit Hall, Grand Canyon Ballroom 6-8

10:50 a.m. – 12:20 p.m.
Plenary II
Moderator: Alexander Pearson, MD, PhD, University of Chicago, Chicago [M]
- An Artificial Intelligence Ultrasound Platform for Screening and Staging of Thyroid Cancer
  Annie Chan, Massachusetts General Hospital, Harvard Medical School, Boston
• Development of a Deep Learning-based Auto-segmentation of Organs at Risk for Head and Neck Radiotherapy Planning
Jihye Koo, University of South Florida, Tampa, Florida

• Safety and Efficacy of RP1 + Nivolumab in Patients with Non-melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-cohort Clinical Trial
Jiaxin Niu, Banner MD Anderson Cancer Center, Houston

• A Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Combinations in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Harrison Cash, MD, University of Washington, Seattle

• EAT During RT: Towards Data-driven Goal Setting for Oral Intake throughout RT as a Function Preservation Strategy
Carly Barbon, MD Anderson Cancer Center, Houston

• Efficacy and Safety of Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma: Results from a Phase II Cohort
David Hong, MD Anderson Cancer Center, Houston

• Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Carcinoma: Results from the Phase II LT-SABR Study
David Sher, University of Texas Southwestern Medical Center, Dallas

• Standard but Not Equal: Disparities in Advanced Radiotherapy Techniques for Head and Neck Cancer in the United States
Neal McCall, Winship Cancer Institute of Emory University, Atlanta

• Focal Adhesion Kinase Drives Resistance to Therapy in HPV-negative Head and Neck Squamous Cell Carcinoma in a P53-dependent Manner
Phillip Pifer, UPMC Hillman Cancer Center, Pittsburgh

12:20 p.m. – 1:20 p.m.
Lunch
Exhibit Hall, Grand Canyon Ballroom 6-8

Early-career and Trainee Networking Luncheon: Launching Your Successful Career
(see page 1 for more information)
Grand Canyon Ballroom 4-5

Experts:
• How to Get Your Paper Published
Maura Gillison, MD, PhD, MD Anderson Cancer Center, Houston [M]
• Finding Personal/Professional Balance
  Cherie-Ann Nathan, MD, Louisiana State University-Heath, Shreveport, Louisiana [HNS]

• Seeking Out and Maintaining Mentoring Relationships
  Zain Husain, MD, Sunnybrook Health Sciences Centre, Ontario, Canada [R]

1:20 p.m. – 2:35 p.m.
Panel: Thyroid
Moderator: Sue Yom, MD, PhD, FASTRO, University of California, San Francisco [R]

• Mutational Landscape of Thyroid Cancers
  Nabil Saba, MD, FACP, Emory University, Atlanta [M]

• Low Risk Thyroid Cancer/RAI
  Jennifer Sipos, MD, The Ohio State University, Columbus, Ohio [Endocrinologist]

• Therapies and Anaplastic Thyroid Cancer
  Saad Khan, MD, Stanford University, Stanford, California [M]

• Multimodality Therapy for Aggressive Differentiated Thyroid Cancers
  Mark Zafereo, MD, FACS, MD Anderson Cancer Center, Houston [HNS]

2:35 p.m. – 3:00 p.m.
Poster Session IV & Coffee Break
Exhibit Hall, Grand Canyon Ballroom 6-8

3:00 p.m. – 4:30 p.m.
HOT TOPIC Options in Advanced Skin Squamous Cell Carcinoma
Moderator: Robert Ferris, MD, PhD, University of Pittsburgh, Pittsburgh [R]

• Controversies in Surgical Management
  Cecelia Schmalbach, MD, MSc, FACS, Temple Health, Philadelphia [HNS]

• Role of Radiation
  Shlomo Koyfman, MD, Cleveland Clinic, Cleveland [R]

• Systemic Therapy
  Jessica Geiger, MD, Cleveland Clinic Cancer Center, Cleveland [M]

• Immunotherapy in Special Populations
  Anne Chang, MD, Stanford University, Stanford, California [Dermatologist]

• Q&A
4:30 p.m. – 5:30 p.m.  
**Development of Survivorship Programs**  
* Moderator: Jon Irish, MD, MSc, FRCSC, FACS, University of Toronto, Toronto, Ontario, Canada [HNS]  
  - **Developing Care Pathways**  
    Liza Blumenfeld, MA, CCC-SLP, BCS-S, University of California, San Diego [SLP]  
  - **Practice and Research**  
    Marci Lee Nilsen, PhD, RN, University of Pittsburgh, Pittsburgh [RN]  
  - **Financial Toxicity**  
    Jonas de Souza, MD, MBA, HCA Healthcare, Nashville, Tennessee [M]  
  - Q&A

**SATURDAY, FEBRUARY 26**

7:00 a.m. – 12:15 p.m.  
**Registration**  
- Registration and Information Desk, Grand Saguaro Foyer

7:00 a.m. – 8:00 a.m.  
**Continental Breakfast**  
- Grand Saguaro Foyer

7:55 a.m. – 8:00 a.m.  
**Welcome**  
Faye Johnson, MD, PhD, MD Anderson Cancer Center, Houston [Physician Scientist]

8:00 a.m. - 8:20 a.m.  
**Patient Perspective**  
David Burkett

8:20 a.m. – 9:45 a.m.  
**De-escalation for HPV**  
* Moderator: Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston [SLP]  
  - **Introduction**  
    Katherine Hutcheson, PhD, MD Anderson Cancer Center, Houston [SLP]  
  - **Surgical Considerations**  
    Umamaheswar Duvvuri, MD, PhD, University of Pittsburgh, Pittsburgh [HNS]  
  - **Radiation Considerations**  
    Bhisham Chera, MD, UNC School of Medicine, Chapel Hill, North Carolina [R]  
  - **Systemic Considerations**  
    Maura Gillison, MD, PhD, MD Anderson Cancer System, Houston [M]  
  - Q&A
9:45 a.m. – 10:30 a.m.
Salivary Cancers
Moderator: Assuntna Gesualda Sacco, MD, University of California, San Diego, Moores Cancer Center, La Jolla, California [M]
- Current Approaches to Managing Salivary Cancer
  Kiran Kakarala, MD, University of Kansas Medical Center, Kansas City, Kansas [HNS]
- Novel Systemic Treatment for Recurrent or Metastatic Salivary Cancers
  Renata Ferrarotto, MD, MD Anderson Cancer Center, Houston [M]
- Q&A

10:30 a.m. – 10:45 a.m.
Coffee Break
Grand Saguaro Foyer

10:45 a.m. – 12:15 p.m.
Recurrent and Metastatic Head and Neck Cancer
Moderator: Farzan Siddiqui, MD, PhD, Henry Ford Cancer Institute, Detroit [R]
- Re-irradiation for Recurrent and Second Primary Head and Neck Cancers
  Neal Dunlap, MD, University of Louisville, Louisville, Kentucky [R]
- Surgical Salvage with Reconstruction
  Urjeet Patel, MD, Northwestern Hospital, Chicago [HNS]
- Novel Targeted and Immunotherapies
  Christine Chung, MD, Moffitt Cancer Center, Tampa, Florida [M]
EXHIBITOR LISTING

**ALPHA TAU MEDICAL LTD.**  
Tabletop: 17

School of Physics, Suite 323  
Tel Aviv University  
P.O. Box 39040  
Tel Aviv 6997801  
Israel  
Phone: 97-236-182-477  
Website: www.alphataumedical.com  

Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company that focuses on R&D and commercialization of the Alpha DaRT technology for the treatment of solid tumors. Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an innovative technology that enables the highly potent and uniquely conformal alpha-irradiation of solid tumors.

**AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO)**  
Tabletop: 24

251 18th Street South  
8th Floor  
Arlington, VA 22202  
Phone: 703-502-1550  
Email: membership@astro.org  
Website: www.astro.org  

ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research and advocacy.

**CASTLE BIOSCIENCES, INC.**  
Tabletop: 30

505 S. Friendswood Drive  
4th Floor  
Friendswood, TX 77546  
Phone: 856-745-4446  
Email: Rbloom@castlebiosciences.com  
Website: www.castletestinfo.com  

Castle Biosciences provides innovative tests with clinically actionable information impacting how skin cancers are diagnosed and managed. Castle Biosciences applies emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes.
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Tabletop:</th>
</tr>
</thead>
<tbody>
<tr>
<td>COHERUS BIOSCIENCES</td>
<td>15</td>
</tr>
<tr>
<td>CRANIOMANDIBULAR REHAB, INC.</td>
<td>29</td>
</tr>
<tr>
<td>ELEVAR THERAPEUTICS</td>
<td>5</td>
</tr>
<tr>
<td>HOOKIPA PHARMA</td>
<td>4</td>
</tr>
</tbody>
</table>

**COHERUS BIOSCIENCES**

333 Twin Dolphin Drive  
Suite 600  
Redwood City, CA 94065  
**Phone:** 650-395-0150  
**Website:** www.coherus.com

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and deliver significant savings. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business.

**CRANIOMANDIBULAR REHAB, INC.**

2600 W 29th Avenue  
Unit 102G  
Denver, CO 80211  
**Phone:** 303-433-8670  
**Email:** schuman@craniorehab.com  
**Website:** www.CranioRehab.com

CranioRehab specializes in head and neck medical devices to treat and prevent complications from head and neck cancer. We strive to make our products affordable and provide insurance billing when possible. Our products treat trismus, tongue strength, xerostomia, mucositis and specialty diets.

**ELEVAR THERAPEUTICS**

2755 E. Cottonwood Parkway  
Suite 540  
Salt Lake City, UT 84121  
**Phone:** 801-303-7440  
**Email:** bstrickland@elevartherapeutics.com  
**Website:** elevartherapeutics.com

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options.

**HOOKIPA PHARMA**

350 Fifth Avenue  
Room/Suite 7240  
New York, NY 10118  
**Phone:** 347-754-2292  
**Email:** susan.trinker@hookipapharma.com  
**Website:** www.hookipapharma.com

HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics.
based on a proprietary arenavirus platform designed to reprogram the body's immune system. Our platform is designed to directly elicit a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defenses against cancers.

**KLARITY**

TABLETOP: 9

600 Industrial Parkway
Heath, OH 43056
Phone: 740-788-8107
Email: eliza@klaritymedical.com
Website: www.klaritymedical.com

Klarity works to improve the daily lives of patients and therapists by providing the most efficient and effective tools for patient positioning. From masks and ovens to Klarity Cushions™, the BiteLok® and beyond, we offer a complete array of modern equipment and products for positioning accuracy. Klarity: Better products for better care.

**KLS MARTIN**

TABLETOP: 27

P.O. Box 16369
Jacksonville, FL 32245-6369
Phone: 904-641-7746
Email: brittany.henshaw@klsmartin.com
Website: www.klsmartinnorthamerica.com

KLS Martin is a company dedicated to producing innovative medical devices for craniomaxillofacial surgery including surgical instruments, distraction osteogenesis devices and power systems.

**KURA ONCOLOGY**

TABLETOP: 10

55 Cambridge Parkway
Suite 101
Cambridge, MA 02142
Phone: 617-588-2614
Email: ellen@kuraoncology.com
Website: www.kuraoncology.com

We are using a precision medicine approach to discover and develop innovative therapies designed to inhibit abnormally functioning cellular pathways that drive cancer growth. Our lead candidate drug, Tipifarnib, is being explored in treatment of patients with selected types of cancer, including HRAS Mutant Squamous Head and Neck Cancers.
MAYO CLINIC  
13400 East Shea Boulevard  
Scottsdale, AZ 85259  
Phone: 480-301-4725  
Email: ryno.patricia@mayo.edu  
Website: www.mayoclinic.org  
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.com and www.mayoclinic.org/news.

MERCK & CO., INC.  
2000 Galloping Hill Road  
Kenilworth, NJ 07033  
Phone: 908-740-4000  
Email: aleida.rosete@merck.com  
Website: www.merck.com  
For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases around the world.

MERCK KGaA DARMSTADT GERMANY  
Frankfurter Strasse 250  
Darmstadt D-64293  
Germany  
Phone: +49 6151 72-0  
Email: lillian.schaff@emdserono.com  
Website: www.merckgroup.com  
Merck is a leading science and technology company in healthcare, life science and performance materials, working to make a positive difference to millions of people’s lives every day. Merck holds the global rights to the Merck name and brand. Exceptions: US and Canada.

MIM SOFTWARE  
25800 Science Park Drive  
Suite 180  
Cleveland, OH 44122  
Phone: 216-455-0600  
Email: ahanley@mimsoftware.com  
Website: www.mimsoftware.com  
MIM Software provides indispensable software that standardizes clinical workflows in Radiation Oncology and helps manage and fully leverage the increasing volume and...
variety of medical imaging required for improved treatment planning. MIM Contour ProtégéAI delivers AI auto-contouring that improves consistency and increases clinical efficiency.

NAVERIS, INC.  
TABLETOP: 12  
22 Strathmore Road  
Natick, MA 01760  
Phone: 415-407-4692  
Email: cyrena.valladares@naveris.com  
Website: www.naveris.com  
Naveris, Inc.™ is a molecular diagnostics company developing and commercializing blood and saliva tests to transform the early detection and clinical management of viral-driven cancers. The company’s NavDx® test, which uses proprietary technology to detect tumor-tissue-modified HPV (TTMV®) DNA, is ordered by 150+ medical centers across the U.S.

ORFIT INDUSTRIES AMERICA  
TABLETOP: 13  
810 Ford Drive  
Norfolk, VA 23523  
Phone: 516-935-8500  
Email: michael.pittman@orfit.com  
Website: www.orfit.com  
Orfit brings high precision and comfort to the positioning and immobilization of cancer patients in radiation oncology. Discover the complete family of Orfit systems for brain, head and neck, supine and prone breast treatment, pelvis and abdomen treatment, SRS, SBRT, extremities, pediatric, MR and proton therapy on www.orfit.com.

QUEST HEALTHCARE, A DIVISION OF QUEST PRODUCTS, INC.  
TABLETOP: 8  
8201 104th Street  
Pleasant Prairie, WI 53158  
Phone: 602-385-1120  
Quest Healthcare provides innovative treatments to improve patients’ quality of living. We use the most forward-thinking technology to transform how providers help patients approach healthcare challenges.  
Alocane Plus® for Radiation Dermatitis & XyliMelts for Xerostomia
Radiation Business Solutions creates value for oncology programs, while creating a better financial experience for patients. Since 2004, we’ve provided oncology-specific strategies to physicians and hospital-based programs, including total revenue cycle management, patient experience programs, referral optimization and new center development.

Reflexion is developing a biology-guided radiotherapy (BgRT)* machine that is the first to use PET to utilize the cancer’s biology itself to guide personalized radiation delivery, even in tumors that are moving. *The Reflexion™ X1 is cleared for SBRT/SRS/IMRT treatments. BgRT is limited by U.S. law to use.

We are building on a rich legacy in oncology with a rejuvenated pipeline and a renewed commitment to bring novel treatment options to patients with unmet medical needs. Today, Sanofi Genzyme has a portfolio of medicines indicated across a variety of cancers, including skin, prostate, lung, colon and breast.

Sanofi Genzyme has a portfolio of medicines indicated across a variety of cancers, including skin, prostate, lung, colon and breast.
Sysmex Inostics, a U.S.-based Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators with ultra-sensitive, quantitative and cost-effective CLIA-validated SafeSEQ NGS liquid biopsy services. SafeSEQ is optimized to ensure the detection of low-frequency mutant molecules (<0.03% MAF) without sacrificing specificity.

**TACTILE MEDICAL**
TABLETOP: 22
3701 Wayzata Boulevard
Suite 300
Minneapolis, MN 55416
Phone: 833-382-2845
Email: jfossey@tactilemedical.com
Website: www.tactilemedical.com
Tactile Medical is a leader in developing and marketing at-home therapy devices for the treatment of lymphedema and chronic venous insufficiency.

**THOR PHOTOMEDICINE**
TABLETOP: 11
5021 Michaels Meadow Drive
Hampstead, MD 21074
Phone: 818-749-5268
Email: jj@thorlaser.com
Website: www.thorlaser.com
THOR Photomedicine is the torchbearer for photobiomodulation (PBM) in oncology. We presented PBM for Oral Mucositis to the US Congress, United Nations and The National Institute for Health and Care Excellence (NICE) in the UK. THOR collaborate with world-class institutions, including Harvard, Stanford University School of Medicine, St. Jude, the University of Pennsylvania, Memorial Sloane Kettering, NYU, The Veterans Administration, the NHS (UK) and more than 50 other research organisations across the globe with an interest in PBM research and patient treatment.

**VARIAN, A SIEMENS HEALTHINEERS COMPANY**
TABLETOP: 19
3100 Hansen Way
Palo Alto, CA 94304
Website: www.varian.com
Varian, a Siemens Healthineers company, is a cancer care technology provider. Our mission is to help create a world without fear of cancer. To that end, our Intelligent Cancer Care™ initiatives harness advanced technologies like artificial intelligence and machine learning to connect clinicians, enhance cancer treatment and expand access to care.
With the onDemand Meeting you will receive:

- Access to 17 hours of educational content.
- Ability to claim up to 17.75 AMA PRA Category 1 Credits™.
- Downloadable PDFs and MP3s of the presentations.
- Ability to review content for three years post-meeting.

After purchasing the onDemand Meeting, you may access it by:

- Log in to your ASTRO account on the ASTRO Academy at academy.astro.org.
- Click the “My Activities” tab.
- Click on the 2022 Multidisciplinary Head and Neck Cancers Symposium onDemand in your “Pending Activities”. Once you have started viewing the sessions, you will access from your “Completed Activities” tab.
- Each session/video will be listed separately for easy access.
- To claim the CME for each session, click on the session, view the video and complete the evaluation.
- You may continue to return to the Head and Neck onDemand to claim CME at your convenience until the course expires in February 2025.

<table>
<thead>
<tr>
<th>Attendee Rate</th>
<th>Non-Attendee Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>$75</td>
<td>$275</td>
</tr>
</tbody>
</table>

FLAT RATE UNTIL 30 DAYS AFTER THE MEETING
(after 30 days, attendees pay the corresponding non-attendee rate)
Upcoming Meetings

2022 ASTRO ANNUAL REFRESHER COURSE
March 25 – 27, 2022
VIRTUAL

2022 ASTRO ADVOCACY DAY
May 16 – 17, 2022
Washington, DC

ASTRO 64TH ANNUAL MEETING
October 23 – 26, 2022
Henry B. González Convention Center
San Antonio, Texas

www.astro.org/meetings
Thank you

Unrestricted Educational Grant Supporter

Merck & Co., Inc.
Thank you
Promotional Sponsors

SILVER LEVEL SPONSORS

CASTLE BIOSCIENCES

Coherus BIOSCIENCES

MERCK
INVENTING FOR LIFE

NAVERIS

BRONZE LEVEL SPONSOR

Prelude Therapeutics